Compare Abeona Therapeutics Inc (ABEO) vs WD 40 Company (WDFC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs WD 40 Company — how do they compare? Abeona Therapeutics Inc trades at $6.75 (market cap $373.32M), while WD 40 Company trades at $244.92 (market cap $3.36B). The key difference: WD 40 Company is far larger — about 9× Abeona Therapeutics Inc's market cap, and WD 40 Company pays a 1.63% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | WDFC | |
|---|---|---|
Market Cap | $373.32M | $3.36B |
Sector | Health | Technology |
52-Week High | $7.23 | $252.96 |
52-Week Low | $4.17 | $187.52 |
Enterprise Value | $228.22M | $3.42B |
Dividend Yield | — | 1.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
WDFC trades at $246.45, up 0.25% with a bullish technical outlook supported by moving averages. The company maintains strong profitability with 55.67% gross margins and recently beat Q1 2026 earnings expectations. Recent corporate developments include executive leadership appointments and a $1.02 quarterly dividend declaration. Revenue growth remains steady with 2026 projections at $636 million, though net income is expected to decline to $80 million.
WDFC presents a mixed investment case with premium valuation metrics (P/E 41.82) offset by consistent profitability and dividend payments. The primary risk involves earnings volatility as seen in recent quarterly misses, while analyst sentiment remains cautious with 71% hold ratings. Upside potential exists if the company can maintain its recent earnings beat trend and execute on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About WD 40 Company
WD-40 Company is a global marketing organization dedicated to creating 'positive lasting memories' by developing and selling products that solve maintenance and cleaning problems. Built around the legendary WD-40 Multi-Use Product, the company operates an asset-light business model, focusing on brand management and innovation while utilizing a network of contract manufacturers to deliver solutions across the Americas, EIMEA, and Asia-Pacific.
Read more on WDFC →
